Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Mann

Showing results (1041-1050 of 1,096) with videos related to

Pageof 110
Sort By:
Nature Medicine|May 25, 2024
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trialHelen M Colhoun, Ildiko Lingvay, Paul M Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 1997
Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamideL K Shawver, D P Schwartz, E Mann, et al.
Diabetes Care|March 29, 2025
Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized TrialsMatthew M Y Lee, Naveed Sattar, Rodica Pop-Busui, et al.
Oral Oncology|January 25, 2018
Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinomaRebecca Hoesli, Andrew C Birkeland, Andrew J Rosko, et al.
Diabetes Care|May 24, 2020
Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized TrialVlado Perkovic, Robert Toto, Mark E Cooper, et al.
The Lancet. Diabetes & Endocrinology|November 28, 2024
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trialsSunil V Badve, Anika Bilal, Matthew M Y Lee, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 5, 2011
Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trialsAusilia Maione, Sankar D Navaneethan, Giusi Graziano, et al.
Diabetologia|April 21, 2022
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trialSimke W Waijer, Priya Vart, David Z I Cherney, et al.
The Journal of Trauma|April 11, 2008
Continuous renal replacement therapy improves survival in severely burned military casualties with acute kidney injuryKevin K Chung, Luis A Juncos, Steven E Wolf, et al.
Nature Medicine|June 24, 2024
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trialJohannes F E Mann, Peter Rossing, George Bakris, et al.
Pageof 110

Showing results (1041-1050 of 1,096) with videos related to

Sort By:
Pageof 110
Nature Medicine|May 25, 2024
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trialHelen M Colhoun, Ildiko Lingvay, Paul M Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 1997
Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamideL K Shawver, D P Schwartz, E Mann, et al.
Diabetes Care|March 29, 2025
Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized TrialsMatthew M Y Lee, Naveed Sattar, Rodica Pop-Busui, et al.
Oral Oncology|January 25, 2018
Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinomaRebecca Hoesli, Andrew C Birkeland, Andrew J Rosko, et al.
Diabetes Care|May 24, 2020
Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized TrialVlado Perkovic, Robert Toto, Mark E Cooper, et al.
The Lancet. Diabetes & Endocrinology|November 28, 2024
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trialsSunil V Badve, Anika Bilal, Matthew M Y Lee, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 5, 2011
Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trialsAusilia Maione, Sankar D Navaneethan, Giusi Graziano, et al.
Diabetologia|April 21, 2022
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trialSimke W Waijer, Priya Vart, David Z I Cherney, et al.
The Journal of Trauma|April 11, 2008
Continuous renal replacement therapy improves survival in severely burned military casualties with acute kidney injuryKevin K Chung, Luis A Juncos, Steven E Wolf, et al.
Nature Medicine|June 24, 2024
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trialJohannes F E Mann, Peter Rossing, George Bakris, et al.
Pageof 110